Breaking

Vaccine breakthrough stops cancer returning in trial Gwyneth Paltrow allegedly set to throw dinner in honor of Sam Altman NASA mission to save its sinking space telescope fails OpenAI seeks to one-up Anthropic with new customer privacy protections Chinese Valentine’s Day is rooted in legend and tradition, not just romance UC Berkeley professor admits to using AI to edit op-ed on students’ math skills Prince Harry emphasizes need to better apply veterans’ skills during roundtable with service members Chinese court sentences Evergrande founder to life in prison for fraud Smuggling in Gaza: How banned goods make it across the border and millions of dollars change hands Judge will consider new trial for Karmelo Anthony in Texas track meet killing

NEWSREEL

The day, in 30-second reels.

--:--:--

Science / Reel

Science · Video brief

Vaccine breakthrough stops cancer returning in trial

A new vaccine developed by Merck and Moderna has shown promising results in stopping skin cancer from returning in trial patients. The vaccine, Intismeran, targets high-risk melanoma after surgery, but experts urge caution as full results a...

BBC News· Aug 20, 2026 · 8:59 AM · 1 views

Video won't play? Watch on YouTube →

A new vaccine developed by Merck and Moderna has shown promising results in stopping skin cancer from returning in trial patients. The vaccine, Intismeran, targets high-risk melanoma after surgery, but experts urge caution as full results await peer review and regulatory approval.

Full story and more reels: https://newsreel.video

#news #breaking #cancerresearch #melanoma #healthcare #vaccines #immunotherapy

Originally reported by BBC News. Read the full story →

More in Science

NASA mission to save its sinking space telescope fails

NBC News· 1 hour ago

Prince Harry emphasizes need to better apply veterans’ skills during roundtable with service members

AP News· 1 hour ago

Relax, everyone: Elon Musk has a mantra to make the climate crisis go away | Emma Brockes

The Guardian· 1 hour ago

0 Comments

No comments yet. Be the first.